Ipamorelin vs MK-677: What the Research Shows
Ipamorelin and MK-677 side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Ipamorelin if…
- you want the option with a randomized human trial, though it found no significant difference from placebo (postoperative ileus): median time to first tolerated meal was 25.3 h vs 32.6 h[6]
Consider MK-677 if…
- you want an oral option with randomized human data: in obese men, MK-677 25 mg daily raised serum IGF-I by about 40% versus placebo over 8 weeks (a hormone outcome)[9]
- you are weighing trade-offs: in that trial an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks[9]
- you want to see a negative human trial: in Alzheimer disease, MK-677 raised serum IGF-1 but was ineffective at slowing disease progression[10]
What they have in common
- WADA prohibits growth hormone secretagogues at all times; its list names ibutamoren (MK-677) and ipamorelin[2]
Spec comparison
Showing 9 of 11 fields where the two differ. FDA status, PCAC vote, Jul 2026 are the same or both unknown.
| Field | Ipamorelin | MK-677 |
|---|---|---|
| Class | GHRP (ghrelin receptor agonist) | Oral ghrelin agonist (not a peptide) |
| Also called | ipa, ipam | ibutamoren |
| FDA status | Not FDA approved · research chemical | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Ipamorelin is named as a growth hormone secretagogue in S2.2.4, prohibited at all times. | No WADA record in our data |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 | [half-life by route] |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: International journal of colorectal disease 2014, PMID 25331030 | [evidence grade] |
| Human studies we summarised | 2 human (2 randomized or controlled) of 12 summarised | [n] |
| Typical study doses |
| [dose range] |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Not in the letters we track |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Different delivery, different kind of trial
In a placebo-controlled trial in obese men, total and visceral fat were not significantly changed with MK-677.[9]
That trial gave obese men MK-677 25 mg (12 men) or placebo (12 men) daily for 8 weeks.[9]
Serum IGF-I rose about 40% with MK-677 compared with placebo.[9]
In an Alzheimer's trial, MK-677 25 mg raised serum IGF-1 but was ineffective at slowing disease progression.[10]
An ipamorelin dose-escalation study infused five rates (4.21 to 140.45 nmol/kg over 15 minutes) in eight healthy men at each dose level.[5]
In a bowel-surgery trial, ipamorelin 0.03 mg/kg or placebo was given by intravenous infusion twice daily from postoperative day 1 to 7 or discharge.[6]
Practical differences that follow from the studies
The Alzheimer's trial randomized 563 patients with mild to moderate disease to MK-677 25 mg or placebo daily for 12 months.[10]
The anti-doping list puts both in the same growth-hormone-secretagogue class, naming ibutamoren (MK-677) and ipamorelin together.[2]
In the ipamorelin infusion study, terminal half-life was short, at 2 hours.[5]
In that Alzheimer's trial, 416 patients completed treatment and assessments at 12 months.[10]
Common questions
Is MK-677 better than ipamorelin?
No head-to-head trial is cited. MK-677's year-long Alzheimer's trial found no benefit despite a higher IGF-1.[10]
Does MK-677 build muscle?
The cited obesity trial found no significant change in total or visceral fat, and its authors say a higher dose or longer treatment would need study.[9]
Is ipamorelin or MK-677 allowed in competition?
Both are named in WADA's prohibited list under growth hormone secretagogues.[2]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 4Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 5Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 6Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 7The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
- 8PubMed search: (ipamorelin[tiab]) AND (ibutamoren[tiab] OR "MK-677"[tiab] OR MK0677[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.The Journal of clinical endocrinology and metabolism · 1998PMID 9467542Accessed 2 Oct 2026
- 10Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.Neurology · 2008PMID 19015485Accessed 2 Oct 2026
Found an error? Report a correction.